ASLAN Pharmaceuticals Pte Ltd Reports Positive Results for Gastric Cancer Treatment

Published: May 29, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

May 28, 2013 -- Aslan Pharmaceuticals Pte reported that ASLAN001 was effective in a Phase II trial among heavily pre-treated gastric cancer patients. ASLAN001, a small-molecule pan-HER inhibitor, reduced cell proliferation and cell survival in gastric tumors that either coexpressed EGFR and HER2 or were HER2 amplified. Aslan, a Singapore based biopharma that in-licenses clinicial-stage assets, acquired global rights to the drug from Array BioPharma in 2011. More details....

Stock Symbol: (NSDQ: ARRY)

Help employers find you! Check out all the jobs and post your resume.

Back to news